Bio-Path Holdings

Bio-Path is a publicly traded biotechnology company focused on developing therapeutic products utilizing its proprietary liposomal delivery technology designed to distribute nucleic acid drugs throughout the human body with a simple intravenous infusion. The Company’s initial focus is on cancer. Bio-Path’s lead product candidate, BP1001 (Liposomal Grb-2), is completing the safety segment of the Phase II for AML in combination with the frontline therapy for induction therapy ineligible patients. A second Phase II safety segment for CML will start in the first half of 2016. Bio-Path’s second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors. Bio-Path's antisense DNA - liposomal delivery technology is called DNAbilize™ and is available for licensing for drug development. DNAbilize™ offers distinct advantages over the current antisense and RNAi therapeutics in development. DNAbilize™ chemistry has shown no toxicity in patients to date. This allows for higher dosing to a therapeutic level compared to the more toxic approaches including phosphorothioate DNA. DNAbilize™ also has the advantage of systemic distribution and allows for targeting genes involved in diseases beyond the liver. Systemic level diseases and disorders can be targeted using DNAbilize™. We are interested in collaborations to develop therapeutics using DNAbilize.
Company Growth (employees)
Type
Public
HQ
Bellaire, US
Founded
2011
Size (employees)
12 (est)+10%
Bio-Path Holdings was founded in 2011 and is headquartered in Bellaire, US

Bio-Path Holdings Office Locations

Bio-Path Holdings has an office in Bellaire
Bellaire, US (HQ)
210 4710 Bellaire Blvd

Bio-Path Holdings Data and Metrics

Bio-Path Holdings Financial Metrics

Bio-Path Holdings's revenue was reported to be $0 in Q1, 2017
USD

Net income (Q1, 2017)

(397 k)

Market capitalization (17-Aug-2017)

26.2 m

Cash (31-Mar-2017)

7.1 m
Bio-Path Holdings's current market capitalization is $26.2 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

13 k

Operating expense total

15.7 m4.5 m5.5 m8.5 m

EBIT

(15.7 m)(4.5 m)(5.5 m)(8.5 m)

EBIT margin, %

(65192%)

Interest income

4 k22.6 k17.7 k12 k

Pre tax profit

(3.3 m)(4.5 m)(5.5 m)

Net Income

(15.4 m)(4.5 m)(5.5 m)(6.8 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

R&D expense

517 k424.5 k592.5 k564.4 k992.4 k1 m1.2 m2.3 m1 m

General and administrative expense

786.4 k566.6 k519.9 k849 k757 k681 k970 k

Operating expense total

517 k424.5 k1.4 m1.1 m1.5 m1.9 m1.9 m3 m2 m

Interest income

6.1 k5.7 k4.3 k5.4 k4.8 k2 k2 k4 k3 k

Net Income

(1.8 m)(2.9 m)(1.4 m)(2.5 m)(4 m)(1.9 m)(3.8 m)(5.4 m)(397 k)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

3.6 m13.9 m8.9 m9.4 m

Current Assets

3.7 m14.1 m9.6 m10.7 m

PP&E

113.1 k72 k614 k

Total Assets

5.1 m15.5 m10.8 m12.2 m

Accounts Payable

76.1 k41 k54.6 k69 k

Current Liabilities

294.9 k562 k937.4 k1.1 m

Total Liabilities

4 m

Additional Paid-in Capital

20.1 m34.7 m35.1 m40.3 m

Retained Earnings

(19.9 m)(25.4 m)(32.1 m)

Total Equity

4.8 m14.9 m9.8 m8.2 m

Financial Leverage

1.1 x1 x1.1 x1.5 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

15.7 m14.6 m12.5 m11.1 m9.9 m6.5 m4.2 m11.3 m7.1 m

Current Assets

16 m14.9 m12.9 m12 m10.5 m7.8 m6.1 m12.4 m8.4 m

PP&E

102.8 k92.6 k82.3 k62 k51 k66 k872 k

Total Assets

17.4 m16.3 m14.2 m13.3 m11.7 m8.9 m7.1 m13.4 m10.1 m

Accounts Payable

78.9 k88.5 k76.6 k385.1 k127.1 k201 k123 k118 k89 k

Current Liabilities

333.5 k283.2 k616.2 k692.2 k481.2 k900 k813 k866 k709 k

Additional Paid-in Capital

34.1 m34.2 m34.8 m34.9 m35 m35.2 m35.4 m40 m40.5 m

Retained Earnings

(18.3 m)(21.3 m)(22.4 m)(23.9 m)(27.3 m)(29.2 m)(30.8 m)(32.5 m)

Total Equity

17 m16 m13.6 m12.6 m11.2 m8 m6.3 m9.4 m8.1 m

Financial Leverage

1 x1 x1 x1.1 x1 x1.1 x1.1 x1.4 x1.2 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(3.3 m)(4.5 m)(5.5 m)(6.8 m)

Depreciation and Amortization

10.3 k41.1 k43 k

Accounts Payable

(34.3 k)267.1 k375.4 k(146 k)

Cash From Operating Activities

(2.3 m)(3.8 m)(5 m)(8.1 m)

Cash From Investing Activities

(123.4 k)(338 k)

Cash From Financing Activities

5.3 m14.2 m9 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(1.8 m)(2.9 m)(1.4 m)(2.5 m)(4 m)(1.9 m)(3.8 m)(5.4 m)(397 k)

Depreciation and Amortization

10.3 k20.6 k30.9 k10 k21 k31 k33 k

Accounts Payable

38.6 k(11.7 k)54.3 k130.2 k(80.7 k)(37 k)(124 k)(71 k)(208 k)

Cash From Operating Activities

(1.6 m)(2.7 m)(1.4 m)(2.8 m)(4 m)(2.4 m)(4.6 m)(6.5 m)(1.8 m)

Purchases of PP&E

(66.1 k)

Cash From Investing Activities

(66.1 k)(25 k)(424 k)

Cash From Financing Activities

13.8 m13.8 m9 m
Y, 2017

Financial Leverage

1.2 x

Bio-Path Holdings Market Value History

Traffic Overview of Bio-Path Holdings

Bio-Path Holdings News and Updates

BRIEF-Bio-Path reported Q2 EPS ($0.02)

* Path Holdings reports second quarter 2016 financial results Source text for Eikon: Further company coverage:

Bio-Path Holdings Company Life and Culture

You may also be interested in